医学
叶黄素
吉西他滨
回顾性队列研究
化疗
胰腺癌
单中心
内科学
外科
肿瘤科
癌症
伊立替康
结直肠癌
作者
Yuta Ushida,Yosuke Inoue,Atsushi Oba,Takafumi Mie,Hiromichi Ito,Ono Y,Takafumi Sato,Masato Ozaka,Takashi Sasaki,Akio Saiura,Naoki Sasahira,Yu Takahashi
标识
DOI:10.1245/s10434-022-11503-6
摘要
BackgroundThe prognosis of initially unresectable pancreatic cancer (UR-PC) has improved since the introduction of FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GNP) treatment. Nonetheless, the indications and optimal timing for conversion to resection remain unclear for UR-PC. The aim of this study is to evaluate the characteristics of cases with initially UR-PC who received modified FFX or GNP treatment.MethodsThis retrospective study reviewed 454 consecutive Japanese UR-PC cases who received modified FFX/GNP treatment. Cases were categorized according to resection status, and overall survival (OS) was evaluated using a multivariable prognostic scoring model (0–4 points, higher score indicating more favorable prognostic factors).ResultsThe overall resection rate was 16% for locally advanced UR-PC (UR-LA) and 5% for metastatic UR-PC (UR-M). The resection group had better OS than the nonresection group (median OS time: not reached versus 13.0 months, P < 0.001). The independent prognostic factors were normalized CA19-9 concentration, modified Glasgow prognostic score of 0, tumor shrinkage after chemotherapy, chemotherapy duration ≥ 8 months, and resection. Cases were grouped according to their prognostic score, and the results suggested that candidates for resection might have prognostic scores of 4 points in UR-M cases or 2–4 points in UR-LA cases.ConclusionsStratification according to prognostic score was useful in predicting the outcomes of UR-PC cases and may aid in identifying cases who might benefit from surgical treatment after responding to chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI